A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

Completed · Phase 2

Conditions studied: Metastatic Breast Cancer

In brief

The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.

Key facts

Study ID: NCT00274469
Run by: AstraZeneca
People needed: 205
Starts: 2006-02-06
Expected to finish: 2017-01-13
Last updated by the study team: 2019-09-06

Who can join

Age: 45 and older, up to 100. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Confirmed hormone receptor positive advanced breast cancer, postmenopausal women

You may not qualify if…

Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).

Where it is running

Research Site — Frederick, Maryland, United States
Research Site — St Louis, Missouri, United States
Research Site — Teaneck, New Jersey, United States
Research Site — Austin, Texas, United States
Research Site — Duncanville, Texas, United States
Research Site — Barretos, Brazil
Research Site — Belo Horizonte, Brazil
Research Site — Goiânia, Brazil
Research Site — Jaú, Brazil
Research Site — Rio de Janeiro, Brazil
Research Site — São Paulo, Brazil
Research Site — Blagoevgrad, Bulgaria
Research Site — Plovdiv, Bulgaria
Research Site — Shumen, Bulgaria
Research Site — Sofia, Bulgaria
Research Site — Sofia, Bulgaria
Research Site — Sofia, Bulgaria
Research Site — Varna, Bulgaria
Research Site — Veliko Tarnovo, Bulgaria
Research Site — Vratsa, Bulgaria
Research Site — Brno, Czechia
Research Site — Brno, Czechia
Research Site — Jičín, Czechia
Research Site — Ostrava, Czechia
Research Site — Prague, Czechia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.